5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 9.37▲ | 9.54▼ | 9.51▼ | 9.16▲ | 9.22▲ |
MA10 | 9.39▼ | 9.55▼ | 9.51▼ | 9.17▲ | 8.89▲ |
MA20 | 9.47▼ | 9.49▼ | 9.30▲ | 9.31▲ | 8.88▲ |
MA50 | 9.54▼ | 9.25▲ | 9.22▲ | 8.84▲ | 8.45▲ |
MA100 | 9.50▼ | 9.23▲ | 9.32▲ | 8.86▲ | 11.97▼ |
MA200 | 9.31▲ | 9.34▲ | 9.09▲ | 8.21▲ | 17.79▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.009▼ | -0.026▼ | 0.010▲ | -0.030▼ | 0.097▲ |
RSI | 39.845▼ | 48.036▼ | 52.189▲ | 53.239▲ | 53.569▲ |
STOCH | 25.410 | 56.901 | 67.872 | 42.328 | 75.391 |
WILL %R | -71.429 | -68.750 | -48.529 | -51.565 | -26.374 |
CCI | -89.184 | -145.348▼ | -46.216 | 35.897 | 95.911 |
Monday, September 08, 2025 08:00 AM
Throughout the last three months, 6 analysts have evaluated Regenxbio RGNX, offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent ratings, showcasing the ...
|
Saturday, September 06, 2025 05:29 AM
Regenxbio's RGX-121 for Hunter syndrome saw its FDA review delayed to February 8, 2026, but strong 12-month surrogate endpoint data supports its ...
|
Friday, September 05, 2025 11:06 AM
Regenxbio (RGNX) announced new, positive data from the Phase I/II/III CAMPSIITE trial of clemidsogene lanparvovec (RGX-121) for the treatment of patients with Mucopolysaccharidosis Type II, also known ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
25/09/25 | 9.41 | 9.73 | 9.1818 | 9.36 | 560,971 |
24/09/25 | 9.05 | 9.58 | 8.9733 | 9.54 | 579,212 |
23/09/25 | 9.05 | 9.12 | 8.80 | 8.93 | 407,546 |
22/09/25 | 8.80 | 9.32 | 8.6837 | 9.06 | 420,899 |
19/09/25 | 9.34 | 9.4004 | 8.875 | 8.89 | 744,618 |
18/09/25 | 9.24 | 9.4825 | 9.17 | 9.36 | 350,021 |
17/09/25 | 9.23 | 9.50 | 8.99 | 9.03 | 308,405 |
16/09/25 | 9.11 | 9.41 | 9.0133 | 9.26 | 290,832 |
15/09/25 | 9.19 | 9.3487 | 8.82 | 9.09 | 387,766 |
12/09/25 | 9.47 | 9.6115 | 9.10 | 9.20 | 294,899 |
|
|
||||
|
|
||||
|
|